Frequently Asked Questions

Galleri® is a multi-cancer early detection (MCED) screening test that looks for a signal across more than 50 cancer types from a single blood draw. It analyzes cfDNA methylation patterns in blood with machine learning. It is not a diagnostic test.

A liquid biopsy is a screening approach that does not require a surgical tissue sample. Tumors shed biomarkers such as cfDNA into the blood from early stages; liquid biopsy tests look for those signals.

It is primarily considered for adults aged 50 and over with additional risk factors such as family history of cancer, long-term smoking or occupational exposure. It is not suitable for pregnant women, individuals aged 21 or under, or those undergoing active cancer treatment. Eligibility is determined by physician evaluation.

Yes — Galleri® is a prescription-only (Rx-only) screening test. If you do not have a physician, we help with physician matching when you submit an information request.

Pricing is per patient; it is shared during the consultation based on the process scope and your individual situation. Contact us for current pricing.

Fill in the information request form or call us. Our team will call you, share the process and pricing, and proceed with the physician prescription and scheduling.

Two options: the Omega Çare home nurse service in all 81 provinces, or the blood draw at the Omega Genetik Beytepe (Ankara) laboratory. It is a single venous sample (2 Streck cfDNA tubes) and no fasting is required.

The result is delivered to your physician approximately 2 weeks after your sample reaches the laboratory. The sample is processed within 7 days of arrival.

The result is delivered to your physician, who discusses it with you. If a signal is detected, the diagnostic road map and genetic counseling support are planned alongside.

In clinical studies, specificity was above 99.5%, positive predictive value 66–77%, overall sensitivity 51.5% across cancers, 76.3% for 12 deadly cancers, and cancer signal origin (CSO) prediction accuracy 93.4% (CCGA, PATHFINDER, NHS-Galleri; 385,000+ participants in total).

A positive result is NOT a cancer diagnosis. It means a cancer signal was detected in your blood along with a predicted origin (CSO); your physician plans the necessary diagnostic work-up.

A negative result means the test did not detect a cancer signal at the time of screening. It does not definitively rule out cancer; you should continue your routine cancer screenings.

When a signal is detected, the test predicts which of 18 anatomic regions it may originate from with 93.4% accuracy. This prediction helps your physician steer the diagnostic work-up.

No. Galleri® does not REPLACE recommended routine screenings such as mammography, colonoscopy and smear; it complements them. You should continue your routine screenings regardless.

It is a liquid biopsy method that captures and analyzes circulating tumor cells (CTC) in the blood of cancer patients. Applied with CellsWay's patented microfluidic technology using just one tube of blood; disease course and treatment response can be monitored through serial measurements.

Galleri® is an MCED screening test applied for additional screening in people without cancer. CellsWay is a CTC test used for monitoring the disease and treatment in diagnosed cancer patients; it is not used for screening. Which one is right for you is determined by physician evaluation.

There are three panels: the CTC Identification Panel (epithelial CTC detection with a CD45⁻/cytokeratin⁺/DAPI⁺ phenotype), the ER/PR/Her2 Panel (especially for breast cancer follow-up) and the PD-L1 Panel (supporting immunotherapy response assessment). Characterization panels are used together with the identification kit.

Results are delivered to your physician as a pathology report within approximately 2 weeks; interpretation is done with physician counseling. The blood draw can be done at home with our nurse service or at our laboratory.

It can be applied to cancer patients who can give blood from a vein; however, it is not applied to patients with hematological cancers and is not used for screening in healthy individuals. The panels are for research use only (RUO); they are not used to guide diagnosis or treatment.

OverC® is a multi-cancer early detection (MCED) test that analyzes methylation marks on cell-free DNA (cfDNA) in blood using next-generation sequencing and machine learning. It looks for signals across six cancer types from a single blood tube (10 mL). It is not a diagnostic test; results are evaluated by a physician.

It screens six cancer types: lung, esophageal, colorectal, liver, pancreatic and ovarian. These are cancers with high incidence and mortality but limited standard screening options. When a signal is detected, the test also predicts which organ may be the source.

OverC® is designed primarily for adults aged 50–75; it may be considered for people with a family history of cancer, lifestyle risk factors (smoking, alcohol, processed meat consumption), HBV/HCV infection or metabolic risks. It is not recommended for pregnant or breastfeeding women, people treated for cancer within the last 3 years, or those who had an infection within the last 14 days. Eligibility is reviewed together with our team at application.

Detecting a signal does not mean a cancer diagnosis. The test predicts the organ that may be the source, guiding further examination. The result is evaluated together with your physician; clinical examination and diagnostic work-up are planned if needed. Our counseling team supports you throughout the process.

The test itself only requires a standard venous blood draw; apart from mild bruising or pain, no risk is expected. What matters is that screening results are interpreted with physician evaluation.

Your health data is protected under KVKK; transfers happen only with service providers necessary for the process and within legal permissions. See the KVKK Privacy Notice for details.

Yes; with your physician's evaluation the test can be repeated at intervals. Follow-up frequency is planned with your physician based on your risk factors and previous results.

Yes. Our center holds the Ministry of Health International Health Tourism Authorization Certificate and accepts foreign nationals residing in Türkiye. The process can be run in Turkish, English or Arabic; you can view our certificates on the About page.

The test requires a prescription. If you do not have a physician, we match you with the most suitable one to assess eligibility and issue it. Prescriptions issued abroad, if any, are evaluated during the consultation.

Coordination and information are provided in Turkish, English and Arabic. The Galleri® report is issued in English; your result is explained with our language support during the consultation with your physician.

Through the Omega Çare network we offer home blood draw service in all 81 provinces. Your sample reaches the laboratory under cold-chain and chain-of-custody rules.

Pricing is per patient; after your consultation, the amount specific to you is sent via a secure payment link. Payment is taken with 3D Secure; the payment options available to you are explained during the call.